Product

Hydroxychloroquine

Aliases
HCQ, Hydroxychloroquine (HCQ) (Cohort B), Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib (6 other aliases)
Name
Hydroxychloroquine Sulfate
INN Name
Hydroxychloroquine sulfate
FDA Approved
Yes

79 clinical trials

29 organizations

120 indications

3 documents

Indication
Tumor
Indication
Solid
Indication
COVID-19
Indication
Healthy
Indication
perihilar
Indication
extrahepatic
Indication
Intrahepatic
Indication
Miscarriage
Indication
Inflammation
Indication
Atherosclerosis
Indication
IgA Nephropathy
Indication
Solid Tumor
Indication
Adult
Indication
Melanoma
Indication
SARS-CoV-2
Indication
Breast Cancer
Indication
Abortion
Indication
Preeclampsia
Indication
Osteosarcoma
Indication
Myocarditis
Indication
Sarcoidosis
Indication
Pulmonary
Indication
Prostate Cancer
Indication
Neuropathy
Indication
Arthritis
Indication
Joint pain
Indication
Advanced Cancer
Indication
melanoma
Indication
Cirrhosis
Indication
Muscle Cramps
Indication
SARS
Indication
pre-eclampsia
Indication
Ovarian Cancer
Indication
Bladder Cancer
Indication
Influenza
Indication
NSCLC
Clinical trial
Hydroxychloroquine for the Management of CVD in CKD
Status: Completed, Estimated PCD: 2024-01-31
Clinical trial
Hydroxychloroquine and Cognitive Function After Surgery
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA)Nephropathy Course QUIgAN Study
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Status: Terminated, Estimated PCD: 2022-11-01
Clinical trial
Study of Anti-Malarials in Incomplete Lupus Erythematosus
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Metabolic Effects of Hydroxychloroquine
Status: Terminated, Estimated PCD: 2022-12-15
Clinical trial
Binimetinib Plus Hydroxychloroquine in KRAS Mutant Metastatic Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Randomised Evaluation of COVID-19 Therapy
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Hydroxychloroquine for Outpatients With Confirmed COVID-19
Status: Completed, Estimated PCD: 2021-10-30
Clinical trial
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
Status: Not yet recruiting, Estimated PCD: 2026-05-31
Organization
Asclemed USA, Inc.
Organization
Northstar Rx LLC.
Organization
AvPAK
Organization
Chartwell RX, LLC